In a presentation at Vitalist Bay, Unlimited Bio CEO Ivan Morgunov and CTO Anna Vakhrusheva spotlighted its ambitious ambition: combining gene therapies to achieve synergistic gains in longevity. The video captures key insights into how the company is pushing beyond single-gene interventions toward integrated, multi-pathway strategies.
Highlights of the Presentation
Synergy Over Single Targets. Unlimited Bio emphasizes that combining therapies (e.g. VEGF, Follistatin, Klotho, BDNF) can produce more than additive effects by reinforcing multiple biological systems.
Strategic Development Stages. The team discussed early-stage plans to test combinations in preclinical settings, optimizing dosing and timing to maximize synergistic benefit while managing safety.
Integration with Lifestyle. The analogy was drawn to lifestyle interventions — diet, exercise, sleep — which already act across multiple pathways; gene therapy combinations are a technological extension of that principle.
Vision & Scaling. Unlimited Bio reinforced its long-term roadmap: evolving from monotherapies to stable, scalable gene-therapy cocktails that can be deployed in human populations.
“If we continue to treat aging as a single dimension, we will always fall short. True rejuvenation requires orchestration across systems.”
The Vitalist Bay showcase underscored Unlimited Bio’s role as a pioneer in the next generation of longevity biotechnology — combining ambition, engineering, and biological insight to push the frontier forward.